To determine the effect of obesity on prognosis in hypertensive subjects, a population of 1727 men 50 to 79 years of age was dichotomized by baseline body mass index (<27 and -27 kg/M2) and systolic blood pressure (< 160 and -160 mm Hg). After 9 years of follow-up, age-adjusted all-cause, cardiovascular, and ischemic heart disease mortality rates were highest in the nonobese hypertensive subjects. The relative risk for mortality associated with a systolic blood pressure of 160 mm Hg or higher was significantly increased only in the nonobese group, with the largest difference in relative risk between obese and nonobese for ischemic heart disease. Results were consistent after separately excluding those with a history of heart disease, diabetes, current use of antihypertensive medication, and cigarette smoking, and those who died within 2 years of the baseline examination. When the independent effect of risk factors, including age, plasma cholesterol level, cigarette smoking, use of antihypertensive medication, and personal history of heart disease or diabetes was assessed with the Cox model, systolic blood pressure was a significant independent predictor of all-cause, cardiovascular, and ischemic heart disease death only in the nonobese subjects. We do not exclude an adverse effect of raised blood pressure in the obese. However, these data suggest that the prognosis is poorer in leaner hypertensive patients than in those who are overweight.
RAISED BLOOD PRESSURE is a well-established risk factor for cardiovascular disease. There is a considerable body of evidence showing a direct relationship between obesity and hypertension. Overweight subjects are more likely to be hypertensive and to develop hypertension; weight changes parallel blood pressure changes, and weight reduction reduces the blood pressure in overweight subjects with essential hypertension. ' Obesity is a weak but possibly independent predictor of cardiovascular disease.' 1 On the other hand, high blood pressure is a strong predictor of cardiovascular disease; after controlling statistically for obesity, both systolic and diastolic blood pressure are predictive of cardiovascular disease independent of associated obesity. '. ' 1 Although it has been stated that obese hypertensive subjects are at greater risk of ischemic heart disease and have higher mortality rates than nonobese hypertensive subjects,2 -1 different cardiovascular phenomena in lean compared with obese hypertensive patients suggest that hypertension might have less clinical significance in obese subjects than in those of more normal weight.'$l`For example, at a given level of blood pressure, leaner hypertensive subjects have more increased peripheral vascular resistance. 17 1' We tested the hypothesis that blood pressure is less predictive of ischemic heart disease death in obese subjects than in nonobese subjects by examining the mortality experience of a population of 1727 men 50 to 79 years of age who have been followed for 9 years. In this population, systolic blood pressure was independently predictive of ischemic heart disease death only in nonobese men.
Methods
Between 1972 and 1974, 82% of an adult upper-middle class Caucasian population in southern California was surveyed for heart disease risk factors (visit 1). Current cigarette smoking. the use of antihypertensive medication, and a personal history of heart disease and diabetes were ascertained by interview with the use of a standardized questionnaire. Patients' height and weight were measured while in light clothing and without shoes; obesity was estimated by the body mass index (weight in kilograms/height in meters squared). Systolic and diastolic blood pressures, first and fifth phase Korotkoff's sounds, were measured with a standard mercury sphygmomanometer and a 14 by 59 mm cuff after the participant had been seated for at least 5 53 BARRETT-CONNOR aInd KHAW min. Any blood pressure greater than 160 mm Hg systolic or 90 mm Hg diastolic was repeated. and the lower of the two measurements was recorded. Total plasma cholesterol was measured in a standardized Lipid Research Clinic laboratory. Approximately 3 months after visit 1. one-third of this cohort (a 15% random sample and all those with hyperlipidemia) had a more extensive evaluation at visit 2. At this visit. blood pressure was measured twice after the subject had been seated for at least 5 min, and the mean of two measurements was used. Height and weight were again measured as above.
Vital status was determined annually for at least 9 years in 99.6% of the total cohort. Death certificates were obtained for all decedents and coded according to the 8th ICDA (International Classification of Diseases, Adapted) by a certified nosologist.
All-cause, cardiovascular (codes 400 to 448). and ischemic heart disease (codes 410 to 414) mortality were recorded. In 30% of the study population, validation of death certificates with any mention of cardiovascular disease was attempted by interview with the next of kin and physician. and by review of hospital records. A panel of cardiologists determined that supporting data confirmed the death certificate diagnosis in approximately 85%.
For the present analysis, all 1727 men 50 to 79 years of age at visit were dichotomized into those who were obese and nonobese. Obesity was defined as a body mass index in the top tertile for this population; this index of 27 or greater is at least 20% above the ideal for men of average build. according to recent Metropolitan Life tables.2'" Risk factor distribution by obesity category was determined. For univariate analyses of mortality rates, the cohort was further divided into systolic (>160 mm Hg and <160 mm Hg) and diastolic (>95 mm Hg and <95 mm Hg) blood pressure categories. Rates were age adjusted to this population by the direct method. The Mantel-Haenszel chi-square test was used to test the age-adjusted, 9
year mortality rates within each obesity category. This analysis was repeated with data obtained at visit 2. For the total cohort, age-adjusted rates and relative risks were also calculated after separately excluding those with a previous history of heart disease or diabetes, those who died within 2 years of follow-up, those who were currently using antihypertensive medication. and current cigarette smokers.
The Cox proportional hazards model2' was used to determine the independent effect of blood pressure on all-cause, cardiovascular, and ischemic heart disease mortality within each obesity category, after adjusting for the effects of age. cholesterol level, cigarette smoking, history of diabetes, history of heart disease, and use of antihypertensive medication.
Finally, to determine whether extremely lean men were responsible for the higher mortality rate in the nonobese group or whether error in blood pressure measurement in the extremely obese22-24 explained the lack of association in the obese, ageadjusted ischemic heart disease mortality rates by systolic blood pressure category were calculated by decile of body mass index.
Overestimation of blood pressure in the obese22-24 has been reported in some but not all studies. We also calculated ageadjusted all-cause, cardiovascular, and ischemic heart disease mortality rates in the obese for those with a systolic blood pressure greater than 170 mm Hg or a diastolic blood pressure greater than 105 mm Hg to examine the effects of overestimation of blood pressure of 10 mm Hg in the obese.
Results
One-third of the 1727 men 50 to 79 years of age were at least 20% above the ideal body mass index,'" i.e., 27 kg/Mr2 or more. Table 1 shows the distribution of selected risk factors in the obese (body mass index >27) and nonobese subjects (body mass index <27). Obese men were significantly more likely to have categorical hypertension and higher mean blood pressures and to be taking antihypertensive medication, but significantly fewer obese men had a past history of heart disease. Diabetes was slightly more common (p < .07) in the obese group. Other risk factors, including age, total plasma cholesterol level, and current cigarette smoking, did not differ significantly between the two groups. The proportion of former or heavy smokers did not differ between the obese and nonobese groups (now shown).
At the 9 year follow-up there were 393, 203, and 146 deaths from all-cause, cardiovascular, and ischemic heart disease, respectively. Table 2 shows ageadjusted all-cause, cardiovascular, and ischemic heart disease mortality rates by body mass index and systolic blood pressure at the 9 year follow-up. Mortality rates were signtficantly higher in the nonobese group with systolic blood pressure of 160 or higher compared with the rest of the cohort; the relative risks for mortality associated with a systolic blood pressure of 160 mm Hg or higher were significantly increased only in the nonobese group, with the largest relative risk differences between nonobese and obese in ischemic heart disease. Results were similar after separately excluding those with a history of heart disease or diabetes, those who died within 2 years of the baseline examina-54 CIRCULATION tion, current cigarette smokers, and those taking antihypertensive medication. Table 3 shows adjusted mortality rates by body mass index and diastolic blood pressure at the 9 year follow-up. Trends were similar, although less marked, to those for systolic blood pressure with highest absolute death rates in the nonobese hypertensive group. Relative risks for all-cause and cardiovascular disease mortality for raised diastolic pressure were increased only in the nonobese group.
Age-adjusted all-cause, cardiovascular, and ischemic heart disease mortality rates in the obese subjects who had systolic blood pressure greater than 170 mm Hg were 31.5%, 18.8%, and 12.3%, respectively, and rates in the obese subjects who had diastolic blood pressure greater than 105 mm Hg were 20.2%, 12.9%, 417; SBP 2 160. BMI < 27. n and 0%, respectively. These rates were still lower than those in the nonobese subjects who had systolic blood pressure greater than 160 mm Hg or diastolic blood pressure greater than 95 mm Hg. Table 4 shows similar age-adjusted rates for the visit 2 sample. The Cox model was used to assess the independent effect of risk factors on all-cause, cardiovascular, and ischemic heart disease mortality separately in the obese and the nonobese groups (table 5). Systolic blood pressure was a significant independent predictor of all-cause, cardiovascular, and ischemic heart disease mortality only in the nonobese subjects. The use of antihypertensive medication was also a significant mortality predictor only in the nonobese subjects. The independent predictive value of other risk factors also differed in the obese and nonobese groups; smoking was predictive of all-cause mortality in the nonobese group and history of diabetes was predictive of mortality in the obese group. A history of heart disease was a stronger predictor of all-cause, cardiovascular, and ischemic heart disease mortality in the nonobese subjects. As shown in figure 1 , this excess ischemic heart disease mortality rate in nonobese men was not limited to the leanest men. Mean diastolic and systolic blood pressure in those with systolic blood pressure of 160 mm Hg or higher or diastolic blood pressure of 95 mm Hg or higher did not differ significantly by decile of obesity or between the obese and nonobese groups, so the lower rates in hypertensive obese subjects were not due to lower mean blood pressures in this group.
Discussion
As previously reported, the mean body mass index in this male cohort was virtually identical to that in the National Health and Nutrition Survey. 25 In this populaategory (based tion, hypertension was predictive of all-cause, cardiovascular, and ischemic heart disease death only in infidence limits) nonobese subjects, even though obese subjects had BMI . 27 significantly more categorical hypertension and higher mean systolic and diastolic blood pressures overall.
3.3D (23-4.7) The increased mortality rate in nonobese hypertensive subjects did not appear to be a function of weight loss 1.1 (0.91.3) after manifest heart disease or diagnosed hypertension; blood pressure and obesity measurements at a second visit in a subsample of this cohort. 1.5 (0.9-2.6)
Both measured blood pressure and the use of antihypertensive medication were significant risk factors 2.5D (1.5-4.2) only in the nonobese subjects. The increased mortality ing selection bias; that is, subjects who were more ill or had more fixed hypertension are more likely to be 1.9 (0.8-4.5) given medication. However, the difference in predictive value of use of antihypertensive medication be- < .001). Others have noted that the correlation of obesity with blood pressure declines with age. ' 28 Since this was a study of older men, we considered the possibility that survivorship bias produced these results. An analysis of the mortality rates in the 599 men 30 to 49 years of age in this population showed only 10 deaths from all causes, including two from ischemic heart disease; both of these men were hypertensive, one obese and one nonobese. Although based on a different birth cohort, these data do not suggest that obese hypertensive subjects are more likely to die than nonobese hypertensive subjects before reaching age 50.
Age-adjusted ischemic heart disease death rates by decile of obesity showed that the poorer prognosis in hypertensive nonobese men was not limited to those in the lowest decile of body weight. The relatively lower mortality in obese hypertensive men could have been caused by misclassification of blood pressure in obese subjects as a consequence of fixed cuff size. Although we cannot entirely exclude this possibility, this phenomenon should be more pronounced in men in the top decile of body mass, but men in the eighth and ninth decile were those with lower ischemic heart disease death rates. Furthermore, assuming a systematic 10 mm Hg overestimation of blood pressure in the obese subjects2-22 we additionally compared age-adjusted death rates in the obese who had systolic blood pressure over 170 mm Hg or diastolic blood pressure over 105 mm Hg with nonobese subjects who had systolic blood pressure over 160 mm Hg or diastolic blood pressure over 95 mm Hg. The hypertensive obese group, so defined, still had lower rates than the hypertensive nonobese group.
These findings are contrary to the conventional wisdom that obese hypertensive subjects experience a greater risk of coronary artery disease than nonobese hypertensive subjects.2 Data in support of this statement are in fact based largely on insurance company and military statistics, where the level of blood pressure is restricted at entry. Among the insured with levels of systolic blood pressure of 140 to 160 mm Hg, overweight curtails the expectation of life among individuals who are both overweight and hypertensive compared with "hypertensive" subjects who are not overweight.'9 However, individuals with blood pressures over 160 mm Hg systolic or 100 mm Hg diastolic were apparently not as adversely affected by the same degree of overweight. Among obese hypertensive Army officers, retirement related to cardiovascularrenal disease was more common in the obese or hypertensive groups alone29; cardiovascular deaths, howev-er, were slightly more common in those who were not overweight.
Many case series of patients with more severe hypertension have found lower mortality rates in obese hypertensive subjects compared with those in nonobese hypertensive subjects. In the series of Frant and Groen,'3 obese hypertensive men had a lower 9 year mortality rate (26%) than nonobese hypertensive men (43%). After more than 25 years of follow-up of 1000 hypertensive patients, Bechgaard3' reported that hypertensive men 40 to 59 years old who were 20 kg above normal weight had a lower mortality rate than patients with no excess weight. In a 10 year follow-up of hypertensive patients at the Mayo Clinic, Breslin et al. found only a slightly greater mortality in individuals 30% overweight; in patients with retinal sclerosis or exudates, the prognosis was better in the obese group. Dimond33 reported that obesity in a hypertensive group of 527 railway employees followed for up to 37 years was not related to the development of coronary disease; in fact, coronary heart disease rates were lowest in the heaviest (although data were not adjusted for age). Similarly, Sokolow and Perloff4 reported that hypertensive patients who were obese had better prognosis than nonobese hypertensive patients.
The results of other studies are partially concordant with our data. In the 10 year follow-up of the Los Angeles Heart study,'3 hypertensive men under 50 years of age who had a higher index of relative weight had a lower incidence of coronary heart disease, although the reverse pattern was seen in older men. In the Framingham 18 year follow-up35 the probability of developing coronary heart disease increased more steeply in men of moderate weight than in obese men; absolute probability rates were also greater in men of moderate weight compared with obese men at higher systolic blood pressure levels, although lean men had lower probability rates than the obese subjects at all levels of systolic blood pressure. However, the 26 year Framingham data reported no evidence of a blood pressure-obesity interaction. 'r Differences between the Framingham results and our data may reflect the greater proportion of men in the former study who were in extremely obese categories where mortality rates were very high. In the Chicago Peoples Gas Company Study,36 the age-adjusted optimal. weight increased when systolic blood pressure was taken into account, a finding consistent with our results. In the Western Collaborative Group Study,7 in men 40 to 59 years old with diastolic blood pressure over 95 mm Hg, coronary heart disease rates in the lean were 1.5 times those in CIRCULATION 58 the overweight subjects. Results from the Australian therapeutic trial38 also found a higher incidence of trial end points, mainly ischemic heart disease, in those with lower body mass index and apparent benefit from treatment was greater in those with lower body mass index.
Like the above studies, the results of the present analysis suggest that the detrimental effect of obesity on blood pressure-associated risk for cardiovascular disease is seen primarily in persons without categorical hypertension. Our data are compatible with an effect of obesity in normotensive subjects, where there was a nonsignificant but consistent slight excess in all-cause, cardiovascular, and ischemic heart disease death in those who were obese compared with those who were not (tables 2 and 3). In the presence of hypertension, however, obesity does not increase risk and, indeed, appears to be protective.
Is it biologically plausible that hypertension is less significant clinically in obese subjects than nonobese subjects? Both the etiology and the pathologic consequences of hypertension may differ in obese or nonobese subjects. Obesity may both potentiate and mitigate harmful cardiovascular effects of hypertension, as has been reviewed by Messerli and colleagues. '6-Raised total peripheral vascular resistance is the hallmark of essential hypertension and the major determinant of systemic hypertensive vascular disease.39 As hypertension becomes established, total peripheral resistance increases and cardiac output reverts to normal.'8 With higher resistance there is contracted intravascular volume,4t'2 concentric left ventricular hypertrophy, and more restricted chamber volume. In obesity the increased stroke volume that augments cardiac output (in response to elevated metabolic requirements)40 4548 is usually associated with an expansion of total blood volume.48 Elevated preload gives rise to left ventricular dilatation and increasing ventricular volume. The compensatory increase in myocardial mass (eccentric left ventricular hypertrophy) remains proportional to chamber dilatation. As a consequence, at a given level of arterial pressure, total peripheral resistance is lower in an obese patient than a lean one.
These results should not be interpreted as an argument in favor of obesity. Obesity increases the risk of hypertension and extreme levels are associated with an increased risk of death. Neither do we exclude an adverse effect of raised blood pressure in the obese.
These data do suggest that in the presence of high blood pressure, the prognosis may be poorer in the leaner subject. This observation may have important implications for interpreting the benefit of the treatment of hypertension. Reference
